Skip to content
Clinical Trials – home

Hospital Marina Baixa De La Vila Joiosa

Research site

Spain Avenida Alcalde En Jaume Botella Mayor 7, 03570 Villajoyosa, Spain

  • 1 trial recruiting
  • Psoriasis · Axial spondyloarthritis · Dermatitis atopic
  • Adults and children

About Specializations

Hospital Marina Baixa De La Vila Joiosa in Villajoyosa, Spain specialises in clinical trials of conditions such as Psoriasis, Axial spondyloarthritis, Dermatitis atopic, HIV infection, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases

The Hospital Marina Baixa De La Vila Joiosa conducts research on disorders where the immune system attacks the body, including Systemic Lupus Erythematosus and Rheumatoid Arthritis. Trials aim to evaluate new biologic agents and compare safety profiles of emerging therapies.

  • Belimumab efficacy in early lupus
  • Baricitinib versus TNF inhibitors for joint disease
  • Immune modulation strategies across autoimmune conditions

The goal is to improve disease control and reduce complications by testing innovative treatments that target immune pathways.

Skin and Connective Tissue Diseases

Studies at the site focus on chronic skin conditions such as Atopic Dermatitis, Plaque Psoriasis, and Nummular Eczema. Research evaluates both topical and systemic therapies to enhance skin clearance and quality of life.

  • Ruxolitinib cream for moderate atopic dermatitis
  • Adjusted brodalumab dosing for heavy patients with severe psoriasis
  • Lebrikizumab effectiveness in nummular eczema

These trials seek to determine the safety and efficacy of novel agents, offering alternatives for patients who have not responded to standard treatments.

Virus Diseases

The department runs several investigations targeting HIV and HIV‑1 infection, focusing on long‑term viral suppression and treatment simplification for diverse patient groups.

  • DTG/3TC maintenance therapy compared with standard regimens
  • Long‑acting cabotegravir plus rilpivirine in adults over 60
  • Switch strategies to injectable therapies for stable patients

The purpose is to assess new therapeutic options that maintain viral control while reducing pill burden and side effects.

Immune System Phenomena

Research also explores fundamental immune system phenomena that underlie multiple diseases, linking insights from dermatology and rheumatology to viral immunity.

  • Cytokine inhibition across psoriasis and ulcerative colitis
  • JAK pathway targeting in atopic dermatitis
  • Biomarker studies to predict treatment response

By deciphering immune mechanisms, the site aims to guide the development of precision medicines for a range of inflammatory and infectious conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida Alcalde En Jaume Botella Mayor 703570 VillajoyosaSpain
Recruiting now
1 trial
Conditions studied
8

More sites in VillajoyosaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

13 clinical trials

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Atopic Dermatitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

HIV infection

Not recruiting

Study of Long-Acting Cabotegravir and Rilpivirine for People Aged 60 and Over Living with HIV-1

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Dermatitis atopic

Not recruiting

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

HIV infection

Not recruiting

Study Comparing DTG/3TC and BIC/FTC/TAF for Maintaining HIV Control in Adults

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Fundacion Seimc Gesida

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.